Hu Rui, Gao Yuan, Wen Yan, Wu Kun, Duan Ci, Zeng Yun, Shi Ming-Xia
Department of Hematology, First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming 650032, Yunnan Province, China,Department of Hematology, The First People's Hospital of Yunnan Province, Kunming 650100, Yunnan Province, China.
Department of Hematology, First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming 650032, Yunnan Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):36-42. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.007.
To investigate regulatory T cells (Tregs) relative content in peripheral blood and bone marrow of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treated with or without decitabine (DAC), analyze the immunomodulatory of Tregs in pathogenesis and remission of MDS and AML, as well as effect of DAC on Tregs.
From October 2018 to February 2019, 15 patients with MDS and 49 patients with AML (newly diagnosed, treated with DAC or other chemotherapy regimens) were enrolled in this study, and 14 cases with iron deficiency or megaloblastic anemia while without malignant tumor and autoimmune disease as controls. The Tregs relative contents in bone marrow and peripheral blood were analyzed by flow cytometry, meanwhile clinical data of the objects were collected.
In peripheral blood and bone marrow of the patients with MDS and AML, the Tregs relative contents at newly diagnosed were higher than those of the control group (P=0.05, P=0.043). The Tregs relative content of AML patients in DAC regimen treatment group was significantly lower than that in the newly diagnosed group and non-DAC chemotherapy group (P<0.05). In DAC regimen treatment group, the Tregs relative contents was significantly lower in remission group than in non-remission group (P<0.05). There was no difference between DAC regimen treatment group and control group in Tregs relative content.
DAC may increase the body's anti-tumor immunity by consuming Tregs content, enhance the body's immune function to identify and kill tumor cells, thereby promote the patients' reliefs.
探讨接受或未接受地西他滨（DAC）治疗的骨髓增生异常综合征（MDS）和急性髓系白血病（AML）患者外周血和骨髓中调节性T细胞（Tregs）的相对含量，分析Tregs在MDS和AML发病机制及缓解过程中的免疫调节作用以及DAC对Tregs的影响。
选取2018年10月至2019年2月期间15例MDS患者和49例AML患者（新诊断，接受DAC或其他化疗方案治疗）纳入本研究，选取14例缺铁性或巨幼细胞贫血且无恶性肿瘤及自身免疫性疾病的患者作为对照。采用流式细胞术分析骨髓和外周血中Tregs的相对含量，同时收集研究对象的临床资料。
MDS和AML患者外周血及骨髓中，新诊断时Tregs相对含量高于对照组（P = 0.05，P = 0.043）。DAC方案治疗组AML患者的Tregs相对含量显著低于新诊断组和非DAC化疗组（P < 0.05）。DAC方案治疗组中，缓解组的Tregs相对含量显著低于未缓解组（P < 0.05）。DAC方案治疗组与对照组的Tregs相对含量无差异。
DAC可能通过消耗Tregs含量增强机体抗肿瘤免疫力，提高机体识别和杀伤肿瘤细胞的免疫功能，从而促进患者缓解。
